Corrigendum to "Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity" [Brain Res. 1178 (2007) 132{box drawings light horizontal}140] (DOI:10.1016/j.brainres.2007.08.033);Complement 3-deficient mice are not protected against MPTP-induced dopaminergic neurotoxicity

Brain Research

Volumn 1178, Issue 1, 2007, Pages 132-140

  Liang, Yajie ^a   Li, Shurong ^b   Guo, Qiang ^a   Zhang, Yanliang ^a   Wen, Can ^a   Zou, Qiang ^b   Su, Bingyin ^a,b  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b CHENGDU MEDICAL COLLEGE   (China)

Author keywords

Complement 3; Knockout mice; MPTP; Neuroinflammation; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; COMPLEMENT COMPONENT C3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT DEFICIENCY; COMPLEMENT SYSTEM; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; FEMALE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SUBSTANTIA NIGRA;

MUS;

EID: 35549009336     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2007.12.011     Document Type: Erratum

References (37)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Rec. 94 (1946) 238-243
2. Barnum S.R., Ames R.S., Maycox P.R., Hadingham S.J., Meakin J., Harrison D., and Parsons A.A. Expression of the complement C3a and C5a receptors after permanent focal ischemia: an alternative interpretation. Glia 38 (2002) 169-173
3. Bezard E., Dovero S., Imbert C., Boraud T., and Gross C.E. Spontaneous long-term compensatory dopaminergic sprouting in MPTP-treated mice. Synapse 38 (2000) 363-368
4. Boos L., Szalai A.J., and Barnum S.R. C3a expressed in the central nervous system protects against LPS-induced shock. Neurosci. Lett. 387 (2005) 68-71
5. Dauer W., and Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39 (2003) 889-909
6. Defazio G., Dal T.R., Benvegnu D., Minozzi M.C., Cananzi A.R., and Leon A. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res. 633 (1994) 206-212
7. Erdei A., Andrasfalvy M., Peterfy H., Toth G., and Pecht I. Regulation of mast cell activation by complement-derived peptides. Immunol. Lett. 92 (2004) 39-42
8. Franklin K., and P.G. The Mouse Brain in Stereotaxic Coordinates (2001), Academic Press
9. Furuya T., Hayakawa H., Yamada M., Yoshimi K., Hisahara S., Miura M., Mizuno Y., and Mochizuki H. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. J. Neurosci. 24 (2004) 1865-1872
10. Gao H.M., Liu B., and Hong J.S. Critical role for microglial NADPH oxidase in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 23 (2003) 6181-6187
11. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17 (2003) 1954-1956
12. Gasque P., Dean Y.D., Mcgreal E.P., Vanbeek J., and Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49 (2000) 171-186
13. Ho A., and Blum M. Induction of interleukin-1 associated with compensatory dopaminergic sprouting in the denervated striatum of young mice: model of aging and neurodegenerative disease. J. Neurosci. 18 (1998) 5614-5629
14. Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., Mcguire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., Gebhard F., Younger J.G., Drouin S.M., Wetsel R.A., and Ward P.A. Generation of C5a in the absence of C3: a new complement activation pathway. Nat. Med. 12 (2006) 682-687
15. Jauneau A.C., Ischenko A., Chatagner A., Benard M., Chan P., Schouft M.T., Patte C., Vaudry H., and Fontaine M. Interleukin-1beta and anaphylatoxins exert a synergistic effect on NGF expression by astrocytes. J. Neuroinflammation 3 (2006) 8
16. Kimura Y., Madhavan M., Call M.K., Santiago W., Tsonis P.A., Lambris J.D., and Rio-Tsonis K. Expression of complement 3 and complement 5 in newt limb and lens regeneration. J. Immunol. 170 (2003) 2331-2339
17. Klegeris A., and Mcgeer P. Complement activation by islet amyloid polypeptide (IAPP) and alpha-synuclein 112. Biochem. Biophys. Res. Commun. 357 (2007) 1096-1099
18. Kurosaki R., Muramatsu Y., Kato H., and Araki T. Biochemical, behavioral and immunohistochemical alterations in MPTP-treated mouse model of Parkinson's disease. Pharmacol. Biochem. Behav. 78 (2004) 143-153
19. Le W., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
20. Liang Y., Li S., Zou Q., and Su B. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice. Neurosci. Lett. 400 (2006) 213-217
21. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., Mcauliffe W.G., Dawson V.L., Dawson T.M., and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403-1409
22. Liu Y., Qin L., Li G., Zhang W., An L., Liu B., and Hong J.S. Dextromethorphan protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. J. Pharmacol. Exp. Ther. 305 (2003) 212-218
23. Loeffler D.A., Camp D.M., and Conant S.B. Complement activation in the Parkinson's disease substantia nigra: an immunocytochemical study. J. Neuroinflammation 3 (2006) 29
24. Markiewski M.M., Mastellos D., Tudoran R., Deangelis R.A., Strey C.W., Franchini S., Wetsel R.A., Erdei A., and Lambris J.D. C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J. Immunol. 173 (2004) 747-754
25. Mastellos D., and Lambris J.D. Complement: more than a 'guard' against invading pathogens?. Trends Immunol. 23 (2002) 485-491
26. Mcgeer P.L., and Mcgeer E.G. Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat. Disord. 10 Suppl 1 (2004) S3-S7
27. Mitsumoto Y., Watanabe A., Mori A., and Koga N. Spontaneous regeneration of nigrostriatal dopaminergic neurons in MPTP-treated C57BL/6 mice. Biochem. Biophys. Res. Commun. 248 (1998) 660-663
28. i signaling in mouse microglia. J. Neurosci. 17 (1997) 615-624
29. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., and Akram M. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety. J. Neurochem. 76 (2001) 1265-1274
30. Robinson S., Freeman P., Moore C., Touchon J.C., Krentz L., and Meshul C.K. Acute and subchronic MPTP administration differentially affects striatal glutamate synaptic function. Exp. Neurol. 180 (2003) 74-87
31. Rus H., Cudrici C., David S., and Niculescu F. The complement system in central nervous system diseases. Autoimmunity 39 (2006) 395-402
32. Shen Y., Halperin J.A., and Lee C.M. Complement-mediated neurotoxicity is regulated by homologous restriction. Brain Res. 671 (1995) 282-292
33. Tatton N.A., and Kish S.J. In situ detection of apoptotic nuclei in the substantia nigra compacta of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice using terminal deoxynucleotidyl transferase labelling and acridine orange staining. Neuroscience 77 (1997) 1037-1048
34. Van B.J., Nicole O., Ali C., Ischenko A., Mackenzie E.T., Buisson A., and Fontaine M. Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. NeuroReport 12 (2001) 289-293
35. Van Beek J., Elward K., and Gasque P. Activation of complement in the central nervous system: roles in neurodegeneration and neuroprotection. Ann. N.Y. Acad. Sci. 992 (2003) 56-71
36. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
37. Yamada T., Mcgeer P.L., and Mcgeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol.(Berl.) 84 (1992) 100-104